Commercialization

New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)

Retrieved on: 
Thursday, November 2, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231102845310/en/
    The Phase 2 trial randomized 155 adult participants with biopsy-confirmed IgAN to monthly intravenous injections of sibeprenlimab 2, 4, or 8 mg/kg, or placebo for 12 months.
  • The primary outcome measure was the change from baseline in 24-hour urine protein-to-creatinine ratio (uPCR) at month 12.
  • The annual eGFR change was −2.7, +0.2, −1.5, and −7.4 ml/1.73 m2 with sibeprenlimab 2, 4, and 8 mg/kg, and placebo, respectively.
  • This reflects a stabilization of eGFR with sibeprenlimab compared to the eGFR decline observed with placebo.1
    The incidence of treatment-emergent adverse events (TEAEs) for patients on sibeprenlimab and placebo was similar.

Otsuka Pharmaceutical Announces Positive Topline Results From Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Retrieved on: 
Friday, October 27, 2023

Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD).

Key Points: 
  • Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD).
  • The first trial (NCT05257265) in adolescents aged 13-17 met its primary endpoint by demonstrating improvements from baseline on the ADHD-RS-5 scale.
  • The second trial (NCT05428033) in children aged 6-12 met its primary endpoint by demonstrating improvements from baseline on the ADHD-RS-5 scale.
  • Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program.

Mass General Brigham Outlines Future of Health Care and Global Integrated Health through Artificial Intelligence at Global Health Exhibition 2023

Retrieved on: 
Friday, October 27, 2023

RIYADH, Saudi Arabia, Oct. 27, 2023 /PRNewswire/ -- Mass General Brigham, a globally recognized health care leader, will participate in the Global Health Exhibition (GHE), scheduled to take place October 29 to 31, 2023, at the Riyadh Front Exhibition and Conference Center (RFECC) in Saudi Arabia. Mass General Brigham's doctors and leadership will help lead a global lineup of speakers discussing crucial healthcare matters important to health care and delivery on the precipice of technological innovation – and the barriers to global adoption.

Key Points: 
  • Mass General Brigham leaders will spearhead conversations and commitments important to how artificial intelligence (AI) can improve diagnostics, patitent outcomes and efficiency in health care.
  • RIYADH, Saudi Arabia, Oct. 27, 2023 /PRNewswire/ -- Mass General Brigham , a globally recognized health care leader, will participate in the Global Health Exhibition (GHE), scheduled to take place October 29 to 31, 2023, at the Riyadh Front Exhibition and Conference Center (RFECC) in Saudi Arabia.
  • Through its many global collaborations with like-minded organzitions, Mass General Brigham is nurturing a new wave of sustainable and transformative evolution in patient care worldwide.
  • For more information about Mass General Brigham's Global Patient Services and Global Advisory Services, please visit:

Mass General Brigham Outlines Future of Health Care and Global Integrated Health through Artificial Intelligence at Global Health Exhibition 2023

Retrieved on: 
Friday, October 27, 2023

RIYADH, Saudi Arabia, Oct. 27, 2023 /PRNewswire/ -- Mass General Brigham, a globally recognized health care leader, will participate in the Global Health Exhibition (GHE), scheduled to take place October 29 to 31, 2023, at the Riyadh Front Exhibition and Conference Center (RFECC) in Saudi Arabia. Mass General Brigham's doctors and leadership will help lead a global lineup of speakers discussing crucial healthcare matters important to health care and delivery on the precipice of technological innovation – and the barriers to global adoption.

Key Points: 
  • Mass General Brigham leaders will spearhead conversations and commitments important to how artificial intelligence (AI) can improve diagnostics, patitent outcomes and efficiency in health care.
  • RIYADH, Saudi Arabia, Oct. 27, 2023 /PRNewswire/ -- Mass General Brigham , a globally recognized health care leader, will participate in the Global Health Exhibition (GHE), scheduled to take place October 29 to 31, 2023, at the Riyadh Front Exhibition and Conference Center (RFECC) in Saudi Arabia.
  • Through its many global collaborations with like-minded organzitions, Mass General Brigham is nurturing a new wave of sustainable and transformative evolution in patient care worldwide.
  • For more information about Mass General Brigham's Global Patient Services and Global Advisory Services, please visit:

Talon Esports, IMG, Warner Music Singapore, MOONTON Games amongst first wave of ESI Singapore 2023 speakers

Retrieved on: 
Tuesday, May 23, 2023

leading B2B esports events and media company, Esports Insider, and

Key Points: 
  • leading B2B esports events and media company, Esports Insider, and
    on 20-21 June at the Asian Civilisations Museum, ESI Singapore is
    set to provide attendees with valuable insights, networking
    stage at ESI Singapore 2023 are:
    Joe Jenkins - Head of Esports, IMG Media
    Gerald Ang - Managing Director, Warner Music
    Ray Ng - Head of Esports Ecosystem, MOONTON
    Gary Ongko Putera - CEO, BOOM Esports
    Debora Imanuella - Senior Vice President, UniPin
    Oh Teck Wee - CFO, Affyn
    Charlie Hanley-Nickolls - Chief Product Officer,
    Mervyn Lai - Managing Director, Playbook
    exceptional lineup of speakers for ESI Singapore 2023.
  • Each speaker
    topics across key tracks such as Commercialisation, Revenues &
    community in APAC is rapidly evolving.
  • With a whole new slate of
    partners such as Warner Music, Krafton and MOONTON Games, the
    & Convention Bureau and its partners including: Main Stage
    Sponsor GRID; Official AV Partner The Gym Esportscentre, Travel
    Official Hotel Partner PARKROYAL COLLECTION Pickering, and media
    to welcome over 400 attendees, with over 40+ speakers across more
    available here .
  • To register or to learn more about the event,

Digerati CEO to take Temporary Medical Leave of Absence

Retrieved on: 
Friday, October 6, 2023

SAN ANTONIO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc. (OTCQB: DTGI) (“Digerati” or the “Company”), a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the small to medium-sized business (“SMB”) market, announced today that CEO Arthur L. Smith will take a temporary medical leave of absence relating to a recent surgery, effective immediately.

Key Points: 
  • SAN ANTONIO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc. (OTCQB: DTGI) (“Digerati” or the “Company”), a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the small to medium-sized business (“SMB”) market, announced today that CEO Arthur L. Smith will take a temporary medical leave of absence relating to a recent surgery, effective immediately.
  • Craig K. Clement, Digerati’s Executive Chairman, will serve as the interim CEO during Mr. Smith’s absence.
  • Mr. Clement stated, “The Board and I have complete confidence in the Company’s ability to continue executing on its strategic initiatives announced last month.
  • He has served as a member of the Company’s Board since 2014 and as Executive Chairman of the Company since 2015.

OSF HealthCare Partners with Summit Venture Studio to License Medical Cart AR App

Retrieved on: 
Thursday, October 12, 2023

LEHI, UT, PEORIA, Ill. , Oct. 12, 2023 /PRNewswire-PRWeb/ -- OSF HealthCare is thrilled to announce a licensing agreement with Summit Venture Studio to commercialize and expand Medical Cart AR, an innovative medical training software developed by OSF Innovation. Medical Cart AR is an augmented reality training application designed to assist health care providers in locating key equipment swiftly during medical emergencies.

Key Points: 
  • OSF HealthCare is thrilled to announce a licensing agreement with Summit Venture Studio to commercialize and expand Medical Cart AR, an innovative medical training software developed by OSF Innovation.
  • Medical Cart AR is an augmented reality training application designed to assist health care providers in locating key equipment swiftly during medical emergencies.
  • LEHI, UT, PEORIA, Ill. , Oct. 12, 2023 /PRNewswire-PRWeb/ -- OSF HealthCare is thrilled to announce a licensing agreement with Summit Venture Studio to commercialize and expand Medical Cart AR, an innovative medical training software developed by OSF Innovation .
  • Medical Cart AR is a health care training application designed to facilitate the rapid location of essential medical supplies during emergencies.

Joint statement by Canada and Sweden on sustained engagement on critical raw materials, battery value chains and emerging technologies

Retrieved on: 
Thursday, October 5, 2023

We agreed to further develop our countries' bilateral cooperation to promote innovation, research, deployment of cleaner technologies including Small Modular Reactors (SMRs) and their supply chains.

Key Points: 
  • We agreed to further develop our countries' bilateral cooperation to promote innovation, research, deployment of cleaner technologies including Small Modular Reactors (SMRs) and their supply chains.
  • We anticipate increased business collaboration and opportunities to foster the development of strong ecosystems with innovative companies from our two countries.
  • Sweden and Canada are committed to deepening and broadening our bilateral engagement to address these challenges, both now and in the future.
  • In the last year alone we have significant commitments to do more in Canada by several Swedish companies.

Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics

Retrieved on: 
Wednesday, October 4, 2023

EDISON, N.J., Oct. 4, 2023 /PRNewswire/ -- The Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization have taken the step of establishing the first spin-off company based on science developed within the Hackensack Meridian Health network. The company aims to make tests detecting cancer and other diseases earlier than ever before.

Key Points: 
  • "This is a remarkable breakthrough for our health network, and for patients of the future," said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health.
  • "We are taking the science produced by our terrific minds at the Hackensack Meridian Health Research Institute, and then moving it to the market so it can benefit all.
  • "This is a new milestone for innovation at Hackensack Meridian Health," said Ihor Sawczuk, M.D., FACS, Hackensack Meridian Health's president of Academics, Research and Innovation, founding chair of the Hackensack Meridian Health Research Institute, and also associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.
  • The Office of Innovation and Commercialization launched in 2022 and promises to support innovations and discoveries across Hackensack Meridian Health.

MHI Introduces New Container-Type Data Center with Immersion/Air-Cooled Hybrid Cooling System

Retrieved on: 
Wednesday, October 4, 2023

- Commercialization planned by the end of FY2023 utilizing technologies related to micro-edge data centers and server cooling.

Key Points: 
  • - Commercialization planned by the end of FY2023 utilizing technologies related to micro-edge data centers and server cooling.
  • TOKYO, Oct 4, 2023 - (JCN Newswire) - Mitsubishi Heavy Industries, Ltd. (MHI) has developed a new 40kVA-class 12ft container-type data center with an immersion/air-cooled hybrid cooling system capable of simultaneously housing servers utilizing three types of cooling methods: immersion cooling (25kVA), air cooling (8kVA), and water cooling (8kVA).
  • The newly developed data center is the successor to the container-type immersion cooling data center(1) that has been under development since 2021.
  • Going forward, MHI Group will apply various cooling technologies and zero emission power products at data centers that utilize high-performance servers.